Skip to content

Registry on Luma Vision's VERAFEYE System (ENLIgHT)

Registry on Luma Vision's VERAFEYE System in Catheter Ablation and Left Atrial Appendage Closure Procedures

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06293430
Acronym
ENLIgHT
Enrollment
50
Registered
2024-03-05
Start date
2027-05-15
Completion date
2027-12-15
Last updated
2026-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Arrhythmia, Atrial Fibrillation, Left Atrial Appendage Closure

Brief summary

The objective of the study is to compile real-world data on the use of the VERAFEYE System in standard of care atrial fibrillation (AF) ablation procedures and left atrial appendage closure (LAAC) procedures.

Interventions

VERAFEYE system guidance will be used on all patients undergoing AF ablation and/or LAAC procedures.

Sponsors

LUMA Vision Ltd.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Key Inclusion Criteria: * Subject is 18 years of age or of legal age to give informed consent specific to state and national law at the time of consent * Subjects is indicated for an atrial fibrillation ablation and/or a left atrial appendage closure procedure with the VERAFEYE System as navigation and imaging system, per physician discretion; * Subject is able to understand and willing to provide written informed consent * Subject is able and willing to complete all study assessments at an approved clinical investigational center Key

Exclusion criteria

* Subjects who have undergone a previous cardiac ablation for the treatment of PAF/LAA Closure * Subject where placement of VERAFEYE Imaging Catheter is technically not feasible per physician discretion * Pregnant women or women who plan to become pregnant during the course of their participation in the study (women should either be of non- childbearing potential at the time of enrolment (as documented in the medical file) or have a negative pregnancy test within the previous 7 days prior to the procedure) * Unrecovered/unresolved Adverse Events from any previous invasive procedure * Subjects who are currently enrolled in another study (except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments)

Design outcomes

Primary

MeasureTime frameDescription
Acute procedural success rates during the index procedureDuring the procedureA procedure will be defined as successful if all the following conditions occur during the case: * ability to create a 3D anatomical model with the VERAFEYE System and * completion of the necessary ablation applications for PAF/LAA Closure using the 3D anatomical model created with the VERAFEYE System

Contacts

CONTACTElke Sommerijns
elke.sommerijns@lumavision.com+32479767156

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 16, 2026